

## **THE REMARKS**

### **The Amendments**

The specification is amended to insert the sequence ID numbers.

The replacement of the first paragraph on page 8 is to insert the sequence ID numbers 16 and 17. The original text of this paragraph was all underlined, therefore, Applicants have to replace the paragraph in order to show the insertion.

New Claim 18 is supported by Example 2.

The amendments of Claim 13 and new Claim 19 are supported on page 16, first full paragraph, lines 4-8.

No new matter is introduced in any of the amendments. The Examiner is requested to enter the amendments.

### **The Response**

#### **Sequence Listing**

Applicants are amending the specification to insert the sequence ID numbers. The sequence listing submitted on September 21, 2005 represents a complete listing of all the sequences disclosed in the application.

#### **Restriction Requirement**

In response to the restriction requirement, Applicants are electing Group I, Claims 1-8, which are drawn to a bivalent or multivalent antibody that binds an epitope on CD3.


In response to the species election requirement, Applicants are electing a diabody.

Claims 1-3 and 5-8 read upon the elected species.

Upon the allowance of a generic claim, Applicant are entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR §1.141.

Date: February 11, 2008

Respectfully submitted,



---

Viola T. Kung, Ph.D. (Reg. No. 41,131)

HOWREY LLP  
2941 Fairview Park Drive, Box 7  
Falls Church, VA 22042  
Tel: (650) 798-3570  
Fax: (650) 798-3600